Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Two GDAC Members Weigh In On Prilosec 1 Without Voting

This article was originally published in The Tan Sheet

Executive Summary

An upcoming publication by FDA's Gastrointestinal Drugs Advisory Committee chairman will suggest a potential link between proton pump inhibitor therapy and the proliferation of pre-existing esophageal adenocarcinoma

You may also be interested in...

OTC Heartburn Drug Uniform Warnings Advocated By Advisory Panels

All OTC heartburn medications should carry stronger warnings alerting consumers about when they may be suffering from a more serious condition, members of FDA's Nonprescription and Gastrointestinal Drugs Advisory Committees recommended

Prilosec 1 Use For GERD Endorsed In 16-2 Joint Committee Vote

Possible long-term use of omeprazole to prevent chronic heartburn or gastroesophageal reflux disease (GERD) is acceptable, despite an OTC indication for only 14-day use, FDA advisory committee members determined at a meeting in Bethesda, Md. June 21

People In Brief

Perrigo promotes in pricing, planning





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts